Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.68 |
| ▸ | AKT2 | P31751 | 20/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3893520 | 0.93 | AKT1 (0.78) | AKT1AKT2KCNH2 | |
| SCHEMBL3904247 | 0.92 | AKT1 (0.78) | AKT1AKT2KCNH2 | |
| SCHEMBL3893812 | 0.92 | AKT1 (0.78) | AKT1AKT2KCNH2 | |
| SCHEMBL3891440 | 0.92 | AKT1 (0.77) | AKT1AKT2KCNH2 | |
| SCHEMBL3893494 | 0.91 | AKT1 (0.79) | AKT1AKT2KCNH2 | |
| SCHEMBL3889603 | 0.90 | AKT1 (0.78) | AKT1AKT2KCNH2 | |
| SCHEMBL3893092 | 0.90 | AKT1 (0.79) | AKT1AKT2KCNH2 | |
| SCHEMBL3890219 | 0.89 | AKT1 (0.79) | AKT1AKT2KCNH2 | |
| SCHEMBL3890226 | 0.89 | AKT1 (0.79) | AKT1AKT2KCNH2 | |
| SCHEMBL3891066 | 0.89 | AKT1 (0.69) | AKT1AKT2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | claimed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | claimed |
| EP-1784175-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| EP-1784175-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006036395-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254901-A1 | Inhibitors of Akt Activity | AKT1, AKT2, PIK3CD | AKT1 1/4885AKT2 2/4885KCNH2 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.